Synta Pharmaceuticals
Keith R. Gollust (Independent Director)
James M. Daly (Independent Director)
Frederick B. Craves (Independent Lead Director)
Summary
History
Founded in 1995, Synta Pharmaceuticals is a research driven pharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs. We have the largest and most diverse pipeline of products in the field. We have successfully developed and commercialized products such as Synthiase, the first novel orally available protease inhibitor, which was approved by the FDA in 2001. We also developed the first inhalable insulin, Apidra, which was approved by the FDA in 2004. Since then, our research and development teams have been working diligently on several projects in the fields of oncology, inflammation/immunology, metabolic/metabolic disorders and skin diseases, to name a few.
Mission
Vision
Key Team
Kenneth M. Bate (Independent Director)
Richard S. Levy (Independent Director)
Paul A. Friedman (Chairman & CEO)
David V. Milligan (Independent Director)
Rebecca A. Taub (Founder, Chief Medical Officer, President of Research & Development and Director)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Keith R. Gollust (Independent Director)
James M. Daly (Independent Director)
Frederick B. Craves (Independent Lead Director)